sector medic suppli devic
messag ew report strong result tavr sale grew impress
yoy investor expect elev come sharp growth
acceler still expect view meaning upsid surpris
next question investor mind like sustain momentum
guidanc manag long-term tavr market forecast continu
assum rapid deceler part impress
posit follow-through low-risk approv think upsid year
outlook still like see revis base case mostli reflect stock
edward tavr busi acceler global sale
cc came consensu momentum driven primarili ramp
procedur volum domest wake august low-risk label expans
estim tavr revenu came roughli top street
impress strength broad-bas manag credit
combin volum gain exist center new site come board follow
recent ncd revis increas referr treatment patient risk
spectrum upsid partial off-set miss intern sale
grew cc edward estim ww tavr volum grew clip
quarter share price hold steadi follow result manag
rais full year tavr growth outlook high end prior cc rang yet
forecast still look somewhat conserv us given signific momentum
market carri model call edward post world-wide tavr
sale cc driven growth gain oversea
see overal tavr market grow ex-fx
rest edward busi segment turn mix result surgic revenu
fell cc short consensu weak driven reduc
savr volum partial off-set continu mix benefit adopt compani
premium price inspiri resilia valv manag maintain
cc full year guidanc express confid perform busi would
improv move continu tavr penetr within low-risk segment
like remain headwind meanwhil critic busi line quarter
revenu cc match consensu growth busi continu
driven hemospher platform edward roll integr version
e-sit oximetri sensor hemospher quarter manag
reiter guidanc critic revenu growth cc
final tmtt revenu miss consensu pascal sale
neg impact voluntari field action quarter edward continu
pursu deliber launch strategi pascal priorit clinic outcom rapid
expans maintain premium price point see prudent approach
near-term especi given legal uncertainti hang franchis litig vs
work way court sever jurisdict abroad
compani still expect tmtt sale meanwhil pipelin front
enrol continu three pascal trial clasp clasp clasp
 pivot trial also set get underway edward yet announc
strategi bring product europ howev abbott announc
receiv ce mark tendyn valv make first compani commerci
breakthrough design fda along approv begin earli feasibl
studi transcathet replac tricuspid valv
page analyst certif import disclosur
incom statement heavi sg spend lower expect
gm drove ep miss despit top-lin upsid edward report gross
margin yoy consensu sg spend rose
yoy sale came street expect
expens increas yoy sale consensu combin
drove ebita margin yoy lower street
project manag cite acceler strateg spend drive tavr therapi
awar expens associ new european medic devic regul
cost relat reloc cardioband manufactur factor contribut
reduc profit final edward tax rate came vs consensu
ad earn despit bump line howev ep still
came street
adjust estim manag rais low end revenu guidanc
call total sale cc vs previous meanwhil
full year ep project
edward run challeng comp back half year see high
end revis rang achiev given compani current momentum
model call ep total revenu
cc compar prior forecast respect view
quarter result posit data point regard overal health tavr market
growth potenti low risk penetr ramp howev ew share trade
revis ntm ep estim vs large-cap med-tech averag see
base case outlook mostli reflect stock current level result prefer
wait better entri point consid becom construct stock
maintain neutral rate
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale come cc edward
busi gener revenu cc work suggest tavr
market track reach sale next four year edward pois
primari beneficiari growth even competit increas howev
street expect tavr growth alreadi high wake low-risk label expans
stock trade signific premium peer ntm ep vs dont
see risk/reward attract current level
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium multipl see
valuat fulli reflect base case scenario tavr adopt
compani growth potenti next year better upsid opportun
elsewher group view remain neutral rate
upsid risk rate fair valu estim includ tavr market growth
exce street expect edward defend leadership posit world-wide
tavr share better forecast tmtt pipelin provid compani
meaning new growth driver sooner anticip
downsid risk rate fair valu estim includ tavr market growth
fall short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
